Prelude Therapeutics Inc (PRLD) Valuation

PRLD Valuation & Fair Value Analysis

Prelude Therapeutics Inc (PRLD) valuation analysis using multiple fair value methodologies. GoodMoat calculates a blended fair value target using discounted cash flow (DCF) analysis, the Graham Number, and earnings-based valuation models.

The GoodMoat Fair Value target for Prelude Therapeutics Inc is $0.97. The current stock price is $5.15, suggesting the stock is 432.0% overvalued.

The price-to-earnings (P/E) ratio is -3.25. Price-to-book ratio is 4.72. Price-to-sales ratio is 26.67. PEG ratio is 0.07.

GoodMoat's valuation models include the Graham Number (based on EPS and book value), an earnings-based model (discounted future EPS), and a PEG-adjusted valuation. The three models are averaged to produce a blended fair value estimate. Use these tools alongside the DCF calculator and reverse DCF to form a comprehensive view of Prelude Therapeutics Inc's intrinsic value.